Olomoucine

A purine derivative that acts as a potent and selective inhibitor of p34cdc2/cyclin B (IC₅₀ = 7 µM) and related kinases, including p33cdk2/cyclin A (IC₅₀ = 7 µM), p33cdk2/cyclin E (IC₅₀ = 7 µM), p33cdk5/p35 (IC₅₀ = 3 µM), and p44MAPK (IC₅₀ = 25 µM). Acts by competing for the ATP binding domain of the kinase. Exhibits reduced sensitivity towards related kinases, p34cdk4/cyclin D1 (IC₅₀ >1 mM) and p40cdk6/cyclin D3 (IC₅₀ >250 µM). Does not significantly affect the activity of other protein kinases even at 1 mM concentrations. Known to inhibit DNA synthesis in interleukin-2 stimulated T lymphocytes and triggers G₁ arrest similar to that observed in interleukin-2 deprived cells. Also used to synchronize cells in G₁.

Cell permeable: no

Primary Target
p34^cdk1/cyclin B

Product competes with ATP.

Reversible: yes

Target IC₅₀: 100 nM-100 µM against p34cdk1/cyclin B

Packaged under inert gas

A 50 mM (5 mg/336 µl) solution of Olomoucine (Cat. No. 495620) in DMSO.

Following initial use, aliquot and refrigerate (4°C).

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Irritant (B)